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Abstract
Extended-spectrum beta-lactamases (ESBL) constitute a key antibiotic-resistance mechanism affecting Gram-negative
bacteria, and also an excellent model for studying evolution in real time. A shift in the epidemiology of ESBLs is being
observed, which is characterized by the explosive diversification and increase in frequency of the CTX-M-type b-lactamases
in different settings. This provides a unique opportunity for studying a protein evolutionary radiation by the sequential
acquisition of specific mutations enhancing protein efficiency and fitness concomitantly. The existence of driver antibiotic
molecules favoring protein divergence has been investigated by combining evolutionary analyses and experimental site-
specific mutagenesis. Phylogenetic reconstruction with all the CTX-M variants described so far provided a hypothetical
evolutionary scenario showing at least three diversification events. CTX-M-3 was likely the enzyme at the origin of the
diversification in the CTX-M-1 cluster, which was coincident with positive selection acting on several amino acid positions.
Sixty-three CTX-M-3 derivatives containing all combinations of mutations under positively selected positions were
constructed, and their phenotypic efficiency was evaluated. The CTX-M-3 diversification process can only be explained in a
complex selective landscape with at least two antibiotics (cefotaxime and ceftazidime), indicating the need to invoke
mixtures of selective drivers in order to understand the final evolutionary outcome. Under this hypothesis, we found
congruent results between the in silico and in vitro analyses of evolutionary trajectories. Three pathways driving the
diversification of CTX-M-3 towards the most complex and efficient variants were identified. Whereas the P167S pathway has
limited possibilities of further diversification, the D240G route shows a robust diversification network. In the third route, drift
may have played a role in the early stages of CTX-M-3 evolution. Antimicrobial agents should not be considered only as
selectors for efficient mechanisms of resistance but also as diversifying agents of the evolutionary trajectories. Different
trajectories were identified using a combination of phylogenetic reconstructions and directed mutagenesis analyses,
indicating that such an approach might be useful to fulfill the desirable goal of predicting evolutionary trajectories in
antimicrobial resistance.
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Introduction
Antibiotic resistance presently constitutes one of the major
factors influencing pathogenesis and the outcome of infections in
antibiotic-exposed patients. Resistance is in fact recognized as one
of the main problems in public health since it is associated with a
high clinical, economic and social impact, and the study of the
antibiotic resistant bacteria has been recognized as a high priority
intervention area (for additional information see documents
‘‘WHO Global strategy for containment of antibiotic resistance’’
in http://www.who.int/drugresistance/guidance/en/index.html,
and ‘‘Action Plan to Combat Antimicrobial Resistance’’ co-
chaired by the Centers for Disease Control and Prevention (CDC),
the Food and Drug Administration (FDA), and the National
Institutes of Health (NIH) in http://www.cdc.gov/DRUGRESIS-
TANCE/actionplan/index.htm). Although strategies for control-
ling the spread of antibiotic resistance have been suggested and
implemented, we have been witnessing an increase in the number
and diversity of antibiotic resistance mechanisms. This is what has
happened with extended-spectrum b-lactamases (ESBLs), and
particularly with the CTX-M-type ESBLs, currently recognized as
the most widespread and threatening mechanism of antibiotic
resistance, both in clinical and community settings [1–3]. Thus, b-
lactamases offer one of the best examples of protein diversification
and evolution as a mechanism of rapid adaptation of bacterial
populations to changing environments [4,5].
Different studies suggest that CTX-M enzymes derive from
chromosomal genes from different Kluyvera species, which have
subsequently spread among pathogenic and non-pathogenic
relevant bacteria [6–9]. It has been recently proposed that the
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unusually high rate of mobilization of blaCTX-M genes from Kluyvera
species to different genetic platforms, as compared with other class
A b-lactamases including those of blaTEM or blaSHV genes [10].
The successful distribution and prevalence of blaCTX-M genes in
comparison to classical blaTEM or blaSHV families in several
ecological niches seem to be related to the interplay of different
selective forces. Firstly, those derived from the association of
blaCTX-M genes with particular genetic platforms (insertion
sequences, integrons, transposons and plasmids) [1,11,12], and/
or specific bacterial clones or clonal complexes [13–15]. Secondly,
the strong selective pressures exerted by the widespread and
concomitant use of different b-lactam antibiotics on clinical
bacteria, driving the emergence and dispersal of novel co-resistant
and more intensely active variants [2,5,16,17].
The adaptive success of particular protein configurations in
CTX-M enzymes is known only from the epidemiological point of
view, but the underlying reasons driving this phenomenon are still
to be understood. To gain insights in this direction, the process of
diversification of blaCTX-M genes was analyzed from an evolution-
ary perspective. Previous analyses based on the similarity of the
corresponding amino acid sequences have shown that CTX-M
ESBLs are grouped into five major clusters (CTX-M-1, -2, -8, -9,
and -25) [10,18]. Since its first description in 1989 [19], more than
80 allelic variants have been recognized, CTX-M-1 and CTX-M-
9 being the most diverse clusters (with 31 and 22 variants
identified, respectively) (www.lahey.org/studies). The first CTX-M
enzymes described displayed a high hydrolytic activity towards
cefotaxime (or ceftriaxone), while remaining poorly active in
hydrolyzing ceftazidime. Nevertheless, many of the CTX-M
variants currently described are able to confer resistance to
cefotaxime/ceftriaxone and also to ceftazidime [20]. Here, we
hypothesize that exposure to ceftazidime in a selective landscape in
which cefotaxime was also present might have constituted the
main selective force driving the evolution of CTX-M enzymes. We
have focused on the CTX-M-1 cluster since it is the most
diversified group and also includes most efficient and ceftazidime-
resistant CTX-M variants described to date.
Some previous studies have identified amino acid positions
involved in the enhancement and/or modulation of the pheno-
typic profile of these enzymes [21–23], while others have provided
important structural insights on the mechanism of action of these
broad-spectrum CTX-M enzymes [24,25]. Nevertheless, we are
far from understand the dynamics of different mutational events at
the molecular level and the accessible evolutionary pathways that
lead to more efficient CTX-M phenotypes, as proposed in other
models [26,27].
The aim of this study was to investigate the different mutational
pathways driving the diversification of blaCTX-M-1-like genes
towards cefotaxime and ceftazidime-resistance phenotypes, and
to establish a hypothetical evolutionary scenario for CTX-M-1-
cluster enzymes. The study increases our understanding of their
evolutionary past and enables us to consider predictive trends in
antimicrobial resistance, a need that has been previously claimed
[28,29].
Results
Phylogenetic reconstruction and detection of positions
under positive selection in the CTX-M-1 cluster
The different phylogenetic tree reconstruction methods used
consistently separated the 73 blaCTX-M and the 12 Kluyvera
sequences analyzed into 5 major clusters (Figure 1), confirming
previous proposals [10,18]. The most closely related sequences to
the CTX-M-1 cluster, blaKLUC-1 and blaKLUC-2 from K. cryocrescens
[6,10,18], were consistently located outside this cluster and the
distance from their hypothetical common ancestor sequence
suggests that the real ancestor of blaCTX-M-1-like genes might still
be unidentified. However, based on this phylogenetic tree, a
putative ancestral amino acid sequence of the CTX-M-1 cluster
was obtained and sequences in the successive nodes derived from
this hypothetical ancestor could also be inferred (Figure 2).
According to this representation, CTX-M-3 and CTX-M-80 b-
lactamases were located in the deepest nodes of the phylogenetic
tree. This hypothetical evolutionary scenario served as reference
for developing our experimental approach.
The phylogenetic analysis showed a successful diversification of
the CTX-M-3 b-lactamase lineage, with at least 25 CTX-M-3 b-
lactamase derivatives. Among these, 64% (16/25) confer resistance
to both cefotaxime and ceftazidime (Figure 2), suggesting that the
diversification process might have been of an adaptive nature,
providing advantages to the harboring strains in a complex
clinical-therapeutical environment. If an adaptive process under-
lies the fast diversification of CTX-M-3, one or several amino acid
positions of this protein might be under positive selection (v=dN/
dS .1). So, the analysis of sequences associated with the CTX-M-
1 cluster (Figure 1) would indicate positions with a v higher than
1, suggesting a fast adaptation of the organisms producing CTX-
M-3-derived enzymes to novel selective challenges. Our analysis
showed that the amino acid positions under positive selection were
77, 114, 167, 240 and 288. On the other hand, when we analyzed
the relative rates of non-synonymous to synonymous substitutions
at those sites for the remaining sequences of the phylogenetic tree
for all CTX-M cluster enzymes, v was lower than 1, thus
indicating that purifying selection was the driving force in these
lineages. This result suggests a slower adaptive evolutionary rate at
the beginning of the diversification process as compared to the
faster amino acid replacement rate observed for the most recent
CTX-M-3-derivative sequences.
Author Summary
Antimicrobial resistance in bacterial organisms is a
worldwide problem widely discussed from clinical, eco-
nomical and social points of view. The number of new
resistance mechanisms and microorganisms resistant to
new drugs is increasing all over the world. The develop-
ment and spread of antibiotic resistance in bacterial
communities represents an excellent model for testing
the predictive potential of evolutionary principles at short
time-scales. A number of studies have tried to predict the
selection of resistant variants when a new drug is
commercialized. However, in many cases there is no
correlation between in vitro predictions and in-field
observations. For this reason, it can be suspected that
the ability to predict the emergence of new resistant
variants might be incomplete unless we know the
evolutionary forces acting on the genetic diversification
processes. Using the CTX-M b-lactamases as a model, a
combination of molecular phylogenetic approaches and
experimental site-specific mutagenesis has allowed us to
establish evolutionary trajectories. We have demonstrated
that two synthetic antibiotics, cefotaxime and ceftazidime,
were the selective forces driving the diversification of CTX-
M enzymes, but only when both antibiotics were
simultaneously present in the environment. We also
predict that, if the current selective landscape is not
modified, variants carrying the mutation D240G will be
more prevalent and diverse in the future.
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reconstruction
In order to assess the influence of the positions predicted to be
under positive selection in CTX-M-1 cluster enzymes on the
increasing bacterial fitness in environments contaminated with
ceftazidime, specific mutations in each predicted site (A77V,
N114D, P167S, D240G and D288N) were introduced by site-
directed mutagenesis into the CTX-M-3 background. A pheno-
typic test (based on the variation of the resistance patterns
observed for different b-lactam antibiotics, especially cefotaxime
and ceftazidime) was carried out. Although the change A140S was
not predicted to be under positive selection, we decided to include
it in this analysis as it appears together with putative positively
selected changes in CTX-M-1, which is included in the most
diversified trajectory (from CTX-M-3) (Figure 2). Therefore, sixty-
three artificial CTX-M-3 variants containing all combinations of
these six changes were constructed (Table 1, suppl. Table S1).
Experimental evolution studies of strains harboring CTX-M-3 in
the presence of increasing ceftazidime concentrations have shown
that mutations in positions 167 (P167S/T, both providing
undistinguishable phenotypes) and 240 (D240G, the unique amino
acid change occurring in this position) are the first ones to be
selected [21,23], and constitute the most efficient variants in
hydrolyzing ceftazidime [1,5,16]. This indicates that the P167S/T
and D240G changes might represent the early steps of two
independent pathways for the diversification of CTX-M-3
enzymes. Despite the simultaneous presence of these mutations
has been shown to produce deleterious effects [23], we cannot
conclude that the pleiotropic antagonism observed between P167S
and D240G mutations would take place in all mutational
combinations and, in consequence, we tested them in all possible
genetic backgrounds. All of them showed decreased hydrolytic
activity against cefotaxime and/or ceftazidime in comparison with
their predecessors carrying only P167S or D240G changes (suppl.
Table S1).
Among all the antibiotics tested, we only observed significant
changes in the resistance levels to cefotaxime and ceftazidime,
whereas the minimum inhibitory concentration (MIC) values of
other b-lactams were only modestly affected (Table 1). CTX-M-3
derivatives constructed by site-directed mutagenesis were thus
ordered towards the most complex (those containing a combina-
tion of all mutations analyzed) and/or successful mutants
(increased MIC values to ceftazidime and/or cefotaxime) leading
to the identification of different presumptive evolutionary
trajectories. The combination of P167S with any other mutation
Figure 1. Phylogenetic tree of blaCTX-M sequences (n=73)
inferred by Bayesian analysis. Support for relevant nodes in the
tree (indicated by a red dot) was estimated by approximate likelihood
ratio, bootstrapping (1000 replicates) with maximum-likelihood recon-
struction, bootstrapping (1000 replicates) with neighbor-joining recon-
struction, and Bayesian posterior probability, color-coded with increas-
ing density of green with the following equivalences: white ,0.80,
lightest green $0.80, light green $0.90, medium green $0.95 and dark-
green $0.99. Kluyvera spp. bla sequences (n=12) from putative
ancestors were included in the analyses and the tree was arbitrarily
rooted with Kluyvera cryocrescens. The discrepancy detected between
this topology and the one generated by Barlow et al., consisting of the
position of the blaCTX-M-11 sequence, might be due to the existence of
two different entries in the PubMed corresponding to this bla gene:
GenBank accession number AY005110 (this study) and AJ310929 [10],
differing in six nucleotides and four amino acid changes, probably
sufficient to ascribe these variants to different branches.
a blaCTX-M-14
and blaCTX-M-18 genes show identical nucleotide sequences;
b blaCTX-M-64
gene corresponds to a hybrid sequence, probably resulting from a
homologous recombination event between blaCTX-M-15 and blaCTX-M-14
genes [32].
doi:10.1371/journal.ppat.1000735.g001
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drastic changes in cefotaxime and/or ceftazidime MICs. On the
contrary, D240G in combination with the same mutations
produced mild changes in the activity of the derived enzymes on
the same antibiotics (Figure 3).
Diversification of CTX-M-1 cluster along the P167
pathway
The diversification of CTX-M-3 enzymes was evaluated
considering the acquisition of the P167S change in the first step,
where ceftazidime seems to be the main driver (from CTX-M-3 to
CTX-M-62) (Figure 4A). This change produces a drastic loss of
enzymatic activity against cefotaxime (from 256 mg/ml to 1 mg/
ml), suggesting that this variant would only be favored by selection
in environments with high exposure to ceftazidime. Among the
subsequent fifteen possible CTX-M-62 derivatives (Figure 4),
seven showed a higher efficiency against ceftazidime. In addition,
the analysis of the deduced diversification trajectories from CTX-
M-62 suggests that only a few mutational pathways are expected to
occur by adaptive evolution. The most complex enzyme included
in this pathway is the mutant CTX-M-3+P167S+A77V+N114D+
A140S+D288N (closely related to the natural variant CTX-M-58),
which confers higher MIC values to both ceftazidime and
cefotaxime than CTX-M-62 (256 mg/ml versus 32 mg/ml, and
12 mg/ml versus 1 mg/ml, respectively).
Ceftazidime could also have played a key role in the ensuing
diversification events since four routes from CTX-M-62 to CTX-
M-58 are possible (Figure 4A). All of them involve a common step,
the acquisition of the change A77V (CTX-M-52, see Figure 4A),
which results in an unchanged ceftazidime MIC value, suggesting
that its emergence was most likely due to genetic drift in finite
populations and a ceftazidime dominant selective landscape. This
double mutant has already been detected both in nature and in
laboratory conditions [23]. In the next step, the fixation of N114D,
A140S or D288N in this background (CTX-M-52) resulted in
increased ceftazidime hydrolytic effects (from 32 to 48–64 mg/ml).
In a similar way, an improved ceftazidime phenotype was
observed in the subsequent steps towards the most evolved and
hydrolytically efficient variant (CTX-M-58, 256 mg/ml), indicat-
ing that almost all trajectories are possible. Indeed, one of them
Figure 2. Phylogenetic reconstruction of CTX-M-1 cluster enzymes. Using the MESQUITE 2.0 program, the amino acid sequence of the
putative CTX-M-1 ancestor was identified, and subsequently all CTX-M-1 cluster variants were positioned in the generated phylogeny. The amino acid
changes acquired in each consecutive step are indicated in each branch. Numbers (n=1–6) up in the figure represent the cumulative number of
amino acid changes present in CTX-M variants with respect to the ancestor sequence. Underlined CTX-Ms represent the variants with activity on both
cefotaxime and ceftazidime.
doi:10.1371/journal.ppat.1000735.g002
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PLoS Pathogens | www.plospathogens.org 4 January 2010 | Volume 6 | Issue 1 | e1000735Table 1. Amino acid changes and b-lactam MIC values associated with CTX-M-3 derivatives constructed in this study.
Mutant
c
GenBank
Acc. Nud CTX-M variant
e Amino acid changes
a
MIC values (mg/ml) of different b-lactam
antibiotics tested
b
A77V N114D A140S P167S D240G D288N CTX CAZ FEP CXM CEF FXT AMC
000000 Y10278 CTX-M-3 256 1 32 .256 .256 2 8
100000 GU125712 + 128 1 1.5 .256 .256 0.5 6
010000 GU125670 CTX-M-30
f + 32 1 8 .256 .256 0.5 8
001000 GU125671 + 32 1 4 .256 .256 1.5 8
000100 GU125668
EF219134
CTX-M-62 + 1 32 0.5 128 192 2 8
000010 AY044436 CTX-M-15 + 128 2 1 .256 256 2 4
000001 GU125665
AY080894
CTX-M-22 + 24 1 2 .256 .256 1.5 8
110000 GU125683 ++ .256 2 6 .256 .256 1.5 8
101000 GU125696 ++ 256 1.5 2 .256 .256 1 6
100100 GU125667
DQ223685
CTX-M-52 ++ 4 32 0.25 64 .256 2 4
100010 GU125662
DQ810789
CTX-M-57 ++ .256 6 1 .256 .256 1.5 4
100001 GU125680 ++ 64 1.5 3 .256 .256 2 8
011000 GU125697 ++ 6 1.5 4 .256 .256 1.5 6
010100 GU125672 ++ 8 .256 4 .256 .256 1.5 16
010010 GU125677 ++ 256 12 3 .256 .256 1.5 4
010001 GU125675 ++ 24 1 8 .256 .256 2 6
001100 GU125669 ++ 1 16 0.5 64 192 3 8
001010 GU125658 ++64 8 1.5 .256 .256 1 4
001001 GU125661 ++ 818.256 .256 1 8
000101 GU125676 ++ 0.5 8 0.094 256 192 1 4
000011 GU125664
AJ549244
CTX-M-28 ++128 4 1.5 .256 .256 1 3
111000 GU125663
EF219142
CTX-M-61 ++ + 16 1.5 0.38 .256 .256 1 4
110100 GU125673 ++ + 8 64 0.5 256 .256 2 4
110010 GU125689 ++ + .256 8 4 .256 .256 1.5 3
110001 GU125693 ++ + 128 2 3 .256 .256 3 8
101100 GU125674 ++ + 4 48 0.25 64 .256 2 4
101010 GU125690 ++ + 256 8 1.5 .256 .256 1 3
101001 GU125703 ++ + 32 1.5 2 .256 .256 1 8
100101 GU125660 CTX-M-23
f ++ + 2 48 0.38 .256 128 1 4
100011 GU125666
EF426798
CTX-M-79 ++ + 256 6 .256 .256 .256 1.5 4
011100 GU125659 + +++ 0.5 12 0.5 .256 128 1.5 4
011010 GU125684 ++ + 256 12 3 .256 .256 1 4
011001 GU125657
AB177384
CTX-M-36 ++ + 12 1.5 1 .256 .256 3 4
010101 GU125682 ++ + 1 16 0.25 .256 128 2 4
010011 GU125706 CTX-M-29
f ++ + 12 4 0.5 .256 .256 1.5 4
001101 GU125692 ++ +2 32 0.25 .256 .256 2 8
001011 GU125686 ++ + 6 2 0.38 .256 .256 1.5 2
111100 GU125701 ++ + + 3 96 0.38 256 .256 1.5 4
111010 GU125704 ++ + + .256 12 4 .256 .256 1 4
111001 X92506 CTX-M-1 ++ + + .256 4 128 .256 .256 1.5 8
110101 GU125698 ++ + + 29 6 0 . 5 .256 128 2 4
110011 GU125687 ++ + + .256 24 16 .256 .256 3 4
101101 GU125699 ++ + + 1.5 32 0.25 .256 128 1 4
Evolutionary Trajectories of CTX-M-1 Group ESBLs
PLoS Pathogens | www.plospathogens.org 5 January 2010 | Volume 6 | Issue 1 | e1000735includes mutant P167S+A77V+D288N, a derivative previously
described in nature (CTX-M-23). In summary, different trajecto-
ries under ceftazidime selective pressure might have occurred, all
of them including CTX-M-52 (P167S+A77V), which constitutes
the mutant with a low probability of being favored by selection.
However, the introduction of cefotaxime in the previous selective
landscape could explain its selection, since it shows an increased
activity against cefotaxime (from 1 to 4 mg/ml) partially restoring
the loss of cefotaxime activity observed in the first step (CTX-M-3
to CTX-M-62, from 256 mg/ml to 1 mg/ml). This suggests that
cefotaxime exposure could also have played a directional role in
the early stages of the diversification process. However, the
evolution from CTX-M-62 to CTX-M-58 in a hypothetical
environment containing only cefotaxime is difficult to explain
Figure 3. Schematic representation of most CTX-M-3 derivative mutants containing P167S or D240G amino acid changes. Light grey
dots represent P167S-carrying mutants, while dark grey dots represent D240G-containing mutants. The size of the dots is directly proportional to the
number of mutants represented in each position (1–2). Their corresponding cefotaxime and ceftazidime MIC values (mg/ml) are shown in the ‘‘x’’ and
‘‘y’’ axis respectively.
doi:10.1371/journal.ppat.1000735.g003
Mutant
c
GenBank
Acc. Nud CTX-M variant
e Amino acid changes
a
MIC values (mg/ml) of different b-lactam
antibiotics tested
b
A77V N114D A140S P167S D240G D288N CTX CAZ FEP CXM CEF FXT AMC
101011 GU125702 ++ + + 256 4 2 .256 .256 0.75 3
011101 GU125679 ++ + + 0.2 3 0.125 .256 96 2 4
011011 GU125707 ++ + + 12 1.5 0.25 .256 .256 1.5 4
111101 GU125713 CTX-M-58
f ++ + + + 12 256 4 .256 .256 2 16
111011 AJ557142 CTX-M-32 ++ + + + 256 8 6 .256 .256 2 4
aAmino acid changes corresponding to non-synonymous substitutions introduced by site-directed mutagenesis in CTX-M-3 in order to obtain the corresponding CTX-M
allele, ‘‘+’’ indicates presence.
bMIC values as determined by E-test to the following b-lactam antibiotics: CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; CXM, cefuroxime; CEF: cephalotin; FXT:
cefoxitine; AMC: amoxicillin-clavulanic acid (2:1).
cThe binary code indicates the content of mutations in each CTX-M variant in this order: A77V, N114D, A140S, P167S, D240G and D288N.
dGenBank accession numbers of blaCTX-M alleles constructed by site-directed mutagenesis in this work and previously described.
eCTX-M-3 derivatives corresponding to natural variants are shown.
fVariants closely related to others described in nature (differing in only one mutation or presenting a different amino acid change).
doi:10.1371/journal.ppat.1000735.t001
Table 1. Cont.
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step site-specific mutagenesis: the P167 pathway. Different CTX-M-3 evolutionary scenarios are shown depending on the acquisition of P167S
(Figure 4) or D240G (Figure 5) mutations in the first step or in the absence of these changes (Figure 7). Each rectangle represents a particular CTX-M-3
derivative obtained by introduction of mutations predicted to be under positive selection (A77V, N114D, P167S, D240G and D288N) and A140S in
cumulative steps towards the most complex mutant (containing all mutations analyzed in each pathway). The binary code indicates the content of
mutations in each CTX-M variant in this order: A77V, N114D, A140S, P167S, D240G and D288N. Variants identical or closely related with enzymes
already detected in nature appear with the corresponding CTX-M designation. Numbers inside the rectangles indicate MIC values (mg/ml) of
ceftazidime (A) or both cefotaxime and ceftazidime (B) observed for MI1443 E. coli cells carrying a recombinant plasmid containing each
corresponding mutant. Possible trajectories identified are shown with arrows. Filled arrows indicate evolutionary steps predicted to be favored by
selection, whereas dotted arrows represent steps associated with neutral events and thus fixed by drift. Deleterious steps (associated with negative
changes in fitness) are not shown. Asterisks indicate significant (using Mann-Whitney tests) increases in MIC between the corresponding mutants.
doi:10.1371/journal.ppat.1000735.g004
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hypothetical intermediates has been found in nature).
Therefore, only the simultaneous presence of both antibiotics
could explain in a satisfactory way the diversification process
leading from CTX-M-3 to CTX-M-58, identifying eight possible
routes (Figure 4B). According to the statistical analysis, the most
probable routes would be P167S+A77V+N114D+A140S (or
D288N)+D288N (or A140S) (Figure 4B). Early in the diversifica-
tion process, the double mutant CTX-M-3+P167S+N114D
yielded ceftazidime and cefotaxime MIC values similar to those
observed for CTX-M-58 and would be selectable according to our
model. Surprisingly, this putative CTX-M variant has not yet been
detected in nature. It is noteworthy that although the presence of
P167S confers the highest ceftazidime MICs, only few of its
derivatives might result in beneficial variations in a mixed
ceftazidime-cefotaxime/ceftriaxone selective landscape. If such
selective framework is maintained in the clinical environment, it
would suggest a limited possibility of evolution and emergence of
new variants in b-lactamases containing P167S/T mutations in
the future.
Diversification of CTX-M-1 cluster along the D240
pathway
The diversification of CTX-M-3 enzymes was also analyzed
considering the initial acquisition of the D240G change. In the first
step, the acquisition of D240G by the CTX-M-3 enzyme
(corresponding to CTX-M-15) resulted in a small increase in the
efficiency in hydrolyzing ceftazidime (from 1 to 2 mg/ml). The
diversification of CTX-M-3 through this route might have
occurred within a more complex scenario than that proposed
above for the P167 pathway since many (n=13) variants showed
higher (although modest) efficiency in hydrolyzing ceftazidime
than CTX-M-15 (Figure 5). Indeed, if ceftazidime were the main
selector agent driving the diversification through the D240 path, at
least nine different mutational trajectories could be identified
towards the most efficient and/or complex variants (Figure 5A).
In the second mutagenesis step, the introduction of the single
amino acid changes A77V, N114D, A140S and D288N in CTX-
M-15 (CTX-M-3+D240G) yielded variants with higher hydrolytic
activity on ceftazidime (from 2 to 4–12 mg/ml) in each case, which
suggests that any of these mutants might have been favored by
selection. Among these, two have already been found in nature:
CTX-M-15+A77V (CTX-M-57) and CTX-M-15+D288N (CTX-
M-28), whereas the most efficient mutant (CTX-M-15+N114D)
has not yet been described (Figure 5A). After a third mutagenesis
step, most resulting combinations could be favored in a
ceftazidime selective environment. Among the selectable combi-
nations, we can find the CTX-M-28+N114D variant (CTX-M-29)
and the mutant CTX-M-57+D288N, whose emergence we
previously predicted [30] and has been subsequently found
in nature (CTX-M-79) [31]. In the fourth directed mutagenesis
step, two out of the four possible derivatives could be favored
by ceftazidime. One of them, the mutant D240G+A77V+
N114D+D288N, eventually derived from CTX-M-29, CTX-M-
79, or other yet undescribed intermediary, carries almost all
positions under positive selection (except P167S) and constitutes
the most efficient variant included in this pathway (ceftazidime
MIC value=24 mg/ml), suggesting that it could be easily favored
by selection.
According to this model, CTX-M-32 (the most complex variant
of this pathway) would not be favored in environments where
ceftazidime is the only selective agent. Nevertheless, and in a
similar way to that proposed for the P167 pathway, the
introduction of cefotaxime in the selective landscape would
explain more easily the emergence of this variant (Figure 5B). In
this hypothetical dual ceftazidime-cefotaxime scenario, the
emergence of the other two intermediates of CTX-M-32 (from
CTX-M-29, CTX-M-79 or from the mutant D240G+A77-
V+A140S) could be favored by selection. Positive selection of
CTX-M-32 would occur in the last step after acquisition of
mutation N114D or A77V under exposure to ceftazidime and/or
cefotaxime (Figure 5B). Hence, different possible routes were
identified from CTX-M-3 to CTX-M-32 by sequential acquisition
of D240G, D288N, N114D, A140S and finally A77V, or D240G,
A77V, A140S (or D288N), D288N (or A140S) and finally N114D.
These pathways include four already described variants (CTX-M-
28, CTX-M-29, CTX-M-57 and CTX-M-79), supporting that this
scenario might have occurred in natural contexts. On the other
hand, the most significant trajectories supported by the statistical
analysis involved i) the sequential acquisition of D240G, A140S,
A77V and N114D; and ii) D240G, D288N, A77V and N114D,
the latter including three already detected variants (CTX-M-15,
CTX-M-28, CTX-M-79).
It is of note that using this model of evolutionary trajectories we
were able to predict many D240G-containing CTX-M-3 deriva-
tives previously detected in nature, which prompts us to suggest
that more D240G-carrying variants might be identified in the
future. In comparison with the P167 path, the D240 evolutionary
pathway is a more plastic route but with limited phenotypic effects,
where the acquisition of different mutations and the build-up of
different mutational combinations have similar phenotypic
outcomes (Figure 3).
A complex network of diversification: from CTX-M-3 to
CTX-M-1
The experimental reconstruction based on directed mutagenesis
of the P167 and D240 pathways suggests that it is possible to attain
the most complex and successful variants via several alternative
routes. While not all of them have necessarily occurred, some are
interconnected, raising difficulties in reconstructing a single
evolutionary history for blaCTX-M-1-like genes. A possible alternative
reconstruction of the phylogenetic relationships among CTX-M-1
cluster enzymes was obtained by median-joining network analysis
(Figure 6). Although such an analysis does not allow inferring the
ancestrality of the whole set of alleles, those that occupy central
positions are considered to represent the most likely ancestors of
each group. Accordingly, CTX-M-3 seems to be next to the basal
line (oldest variant) since it is at one amino acid change distance
from seven known alleles and four yet-unknown (intermediate)
variants, and its average distance to the remaining alleles in this
group is the lowest (1–5 changes). This observation is congruent
with the maximum-likelihood tree shown in Figure 2 and with the
results presented by Barlow et al. [10] (see above). The network is
characterized by a high level of homoplasy, involving only a few
amino acid positions such as 167, 240 and 288, which indicates
that a minimum number of amino acid changes explains the
derivation of any allele from its ancestors in the group.
Independence between the two main previously described
pathways P167 and D240 may be suspected from the analysis of
Figure 6, as the only common nodes among them consist of CTX-
M-3 (oldest variant) and CTX-M-22 (CTX-M-3+D288N). The
median-joining network analysis could suggest a third possible
diversification pathway, leading to the evolution from CTX-M-3
towards CTX-M-1 from which CTX-M-58 or CTX-M-32 could
easily emerge through the acquisition of P167T or D240G
mutations, respectively, in the last step. CTX-M-1 differs from its
putative ancestor (CTX-M-3) by four amino acid changes (A77V,
N114D, A140S and D288N), three of which (A77V, N114D and
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step site-specific mutagenesis: the D240 pathway. See legend for Figure 4.
doi:10.1371/journal.ppat.1000735.g005
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processes through ceftazidime and cefotaxime exposure, suggest-
ing that similar selective forces have contributed to the
diversification from CTX-M-3 to CTX-M-1. Since CTX-M-1
yielded a four-fold increase (from 1 to 4 mg/ml) in the MIC value
for ceftazidime, the sequential acquisition of mutational changes
from CTX-M-3 leading to CTX-M-1 was analyzed experimen-
tally and the possible hypothetical evolutionary scenarios were
considered (Figure 7).
If ceftazidime were the only selective driver, the introduction in
the first step of each single mutation in the blaCTX-M-3 background
by means of site-directed mutagenesis did not yield any variant
with increased activity on ceftazidime (Figure 7A). In the second
and consecutive steps, all possible intermediates including also
CTX-M-1 would arise in the population. Although some of these
intermediates might emerge through positive selection (favored by
small increases in ceftazidime MIC values), all hypothetical
trajectories include at least one intermediate that can only be
explained by drift (e.g. the known variants CTX-M-22, CTX-M-
30 or CTX-M-61). If we consider a heterogeneous ceftazidime-
cefotaxime environment, as proposed in the two main P167 and
D240 pathways (see above), only 6 trajectories in the evolution
from CTX-M-3 to CTX-M-1 involve steps favored by selection,
with the sole exception of the first step, reducing the probability of
these trajectories to have occurred in a selective environment
(Figure 7B). According to the median-joining network reconstruc-
tion of the enzymes in the CTX-M-1 cluster already detected in
nature (Figure 6), one of these six trajectories might have occurred.
This possible route involves the neutral acquisition of N114D in
the first step. In a second step, the introduction of the A140S
mutation would result in a slight increase in the ceftazidime MIC
value (from 1 to 1.5 mg/ml), while the cefotaxime resistance level
would decrease (from 32 to 6 mg/ml). In the next step, the
introduction of A77V or D288N would yield CTX-M-61 and
CTX-M-36 variants respectively, partially restoring cefotaxime-
hydrolyzing activity (from 6 to 12–16 mg/ml). Finally, the
introduction in the last step of D288N or A77V, respectively,
would generate CTX-M-1 (Figure 6, Figure 7B). From CTX-M-1,
the highly efficient enzymes CTX-M-32 (CTX-M-1+D240G) and
CTX-M-58 (CTX-M-1+P167T) could easily emerge. In addition,
the introduction of P167S or D240G could also have occurred at
intermediate stages, as inferred by both the site-specific mutagen-
esis approach and the median-joining network analysis. For
instance, the emergence of CTX-M-23 or CTX-M-28 b-
lactamases (included in the P167S and D240G, respectively),
could also have occurred in CTX-M-3 by the sequential
Figure 6. Median-joining network inferred for CTX-M-1 group amino acid sequences. Numbers next to the segments connecting nodes
denote the amino acid position inferred to have changed between the two connected alleles. Large dots represent CTX-M variants detected in
natural contexts, which differ in the presence of mutations in positions evolving under positive selection (A77V, N114D, P167S, D240G, D288N) as
follows: blue dots represent variants containing the P167S mutation alone (light blue) or associated with others (dark blue); green dots represent
alleles containing the D240G change alone (light green) or associated with others (dark green); yellow dots represent variants containing mutations
A77V, N114D and/or D288N; white dots represent variants containing mutations in other positions presumptively not subjected to positive selection.
Alleles whose existence is postulated by the analysis but which have not yet been identified are represented by small red dots in the corresponding
nodes.
doi:10.1371/journal.ppat.1000735.g006
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doi:10.1371/journal.ppat.1000735.g007
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tively (Figure 2), indicating the possibility of connections between
this third path and the two main routes (Figure 8).
Discussion
In this project, the possible existence of selective antibiotic
drivers leading to the diversification of CTX-M-3 derivative
enzymes has been studied. Our data indicate that the exposure of
bacterial populations to synchronic or diachronic challenges with
ceftazidime and cefotaxime seems to have played a critical role in
the explosive diversification of CTX-M variants, and we suggest
that the most evolved enzymes are those with high-level, balanced
resistance to both drugs. Although we have not observed
significant changes in the MIC values of other clinically used b-
lactam antibiotics tested (Table 1), we cannot totally exclude the
possible contribution of other antibiotics in the diversification
process (e.g. cephalosporins of veterinary use) [17]. Similarly,
alternative explanations cannot be discarded, including diversify-
ing selection events, such as recombination [32], or alternative
selective processes, such as possible physiological effects of some
mutations in specific CTX-M variants in the absence of antibiotic
exposure [33].
A mutational landscape model [34] similar to the one proposed
to explore the step-by-step molecular evolution of TEM b-
lactamases [27] was applied here to understand the evolution of
CTX-M. The basic hypotheses were: i) a higher fitness is provided
by mutations increasing both cefotaxime and ceftazidime MICs in
environments contaminated by these antibiotics; and ii) conse-
quently, the direction of the evolution of CTX-M-3-derived
variants should be towards those yielding higher joint MICs, such
as CTX-M-32. The assumption that relates higher fitness with
increased MICs is based on two notions: a) only organisms able to
resist high antibiotic concentrations will survive in environments in
which these concentrations are frequently present (such as urine);
b) organisms able to resist high b-lactam concentrations should be
selected over those with lower resistance levels in antibiotic
gradients that are formed on human surfaces and tissues [35].
Considering the larger extension of the areas with low antibiotic
concentrations, high-resistance levels ensure higher fitness in wider
spaces. Increased fitness derives from this ‘‘larger selective
compartment’’ [36,37].
CTX-M mutants containing the change P167S seem to be the
most successful in generating highly effective variants acting on
ceftazidime in a few steps (Figure 3). However, out of the thirty-
one possible mutational combinations from CTX-M-62 (CTX-M-
3+P167S) constructed in this work, only fifteen yielded an
increased efficiency at hydrolyzing ceftazidime and/or cefotaxime,
and only three of them have been detected in nature (Figure 4,
suppl. Table S1). The analysis carried out in this study indicates
that only a few mutational routes towards the highest fitness peak
variants are reachable by Darwinian selection, and that many of
the remaining trajectories have very low probabilities of
realization, as it was shown with TEM-enzymes [27,38]. Such
constraints in this evolutionary network indicate that once
optimum or near-optimum variants are readily selected (as the
CTX-M-3 variant carrying P167S+N114D changes), novel
mutants emerging on the peak will precipitously decrease their
efficiency in a ceftazidime-cefotaxime environment, which can be
illustrated as the existence of single high fitness peak surrounded
by steep cliffs [26].
On the contrary, mutants included in the D240 pathway
showed modest effects on fitness, which suggests that many
alternative trajectories with common intermediate genotypes
might produce a similar phenotype (Figures 3 and 5). Therefore,
these trajectories are connected and their connectedness implies
(results in) some degree of robustness in the system [39]. In this
case, the mutational landscape resembles a relatively low peak with
a relatively flat surface surrounded by smooth slopes. Indeed,
selection may favor populations that occupy lower peaks
surrounded by less precipitous mutational chasms [40]. Consis-
tently with this description, out of the thirty-one CTX-M-15
(CTX-M-3+D240G) derivative mutants, twenty-three had an
increased fitness and five corresponded to CTX-M enzymes
already found in nature (Figure 5, suppl. Table S1).
The P167 pathway assures a good adaptation (high fitness) to
high concentrations of ceftazidime (MICs of 3-.256 mg/ml versus
1.5–24 mg/ml for the D240G pathway), but it is fragile in yielding
resistant variants able to survive in the presence of ceftazidime and
cefotaxime. On the contrary, the D240 pathway offers lower levels
of resistance to ceftazidime, but it is robust in yielding variants able
to survive in the presence of both drugs. Therefore, more CTX-
M-1 variants will probably emerge in the D240 genetic landscape.
In addition, cells producing CTX-M variants carrying both P167S
and D240G changes in all possible genetic backgrounds
consistently showed lower MIC values to cefotaxime and/or
ceftazidime than the correspondent P167S or D240G immediate
ancestors (suppl. Table S1). These data support the hypothesis that
P167 and D240 pathways represent independent routes of
diversification [23].
A third possible diversification pathway is proposed, where
neither P167S nor D240G were selected in the first stage of the
process, and where neutral drift might be significant in the initial
steps. The role of drift in early stages of b-lactamase evolution
might be significant in conditions of low genetic load and high
Figure 8. Interconnectedness of three CTX-M-3 diversification
routes. Circles represent CTX-M-3 mutant derivatives associated with
the different evolutionary routes towards the most evolved variants: i)
P167 pathway (blue), ii) D240 pathway (green) and iii) evolution
towards CTX-M-1 (yellow). The color gradient represents the direction
of evolution.
doi:10.1371/journal.ppat.1000735.g008
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increased mutation rates have been frequently observed in strains
harboring CTX-M b-lactamases [43,44]. Although this path
shows a very flat fitness landscape (next to neutrality) it allows us to
explain the selection of several variants like CTX-M-36 and CTX-
M-61 (Figures 6 and 7). Moreover, this pathway provides
alternative routes for the selection of some CTX-M enzymes,
such as CTX-M-23 or CTX-M-28 predicted in the P167 or D240
pathways respectively, suggesting that the interconnection between
this route and the two previous trajectories would facilitate the
emergence of new variants, as illustrated in Figure 8.
This study shows a high congruence between phylogenetic
reconstruction analysis and step-by-step site-specific mutagenesis,
allowing different presumptive evolutionary trajectories to be
identified. Such combination of theoretical phylogenetic recon-
struction and directed mutagenesis might be useful to analyze and
eventually predict evolutionary antimicrobial resistance trajecto-
ries. Whereas the phylogenetic reconstruction analyses inform
about the most likely trajectories actually followed based only on
existing nucleotide changes, mutants experimentally constructed
by site-directed mutagenesis were ordered according to their
increased resistance phenotypes to ceftazidime and/or cefotaxime.
This allowed the identification of a higher number of possible
trajectories than those derived from the phylogenetic analysis, as it
included all possible intermediate CTX-M alleles, though only
some have actually been detected in nature. Therefore, we cannot
rule out the existence of non-described variants belonging to other
trajectories or the contribution of non-identified selective con-
straints. In addition, it should be noted that the fixation of a given
intermediate variant is not necessarily required for the appearance
and increase in frequency of a further fitness-increasing mutant.
On the other hand, the successful distribution of a given CTX-M
variant (increase in frequency) is influenced not only by its relative
fitness, but also by the genetic platforms responsible for its
mobilization (ISEcp1,I S CR1,I S 26 and phage-like) and dissemi-
nation (integrons, transposons, plasmids and/or clones). This is the
case of CTX-M-1, CTX-M-3, CTX-M-15 or CTX-M-32
enzymes, which are successfully disseminated in specific genetic
units even though they do not constitute the most successful
variants in our experimental conditions [15].
The results shown in this work might well apply to other CTX-
M clusters. An alternative reconstruction of the phylogenetic
relationships among blaCTX-M alleles was obtained by median-
joining network analysis (Figure 9). This analysis revealed the
central role of CTX-M-2 and CTX-M-14 in the diversification of
the CTX-M-2 and CTX-M-9 clusters respectively, similar to that
of CTX-M-3 in the CTX-M-1 cluster.
In conclusion, we suggest that the selective force pushing allelic
diversification derived from CTX-M-3 was the ability of these
CTX-M variants to provide better protection of the bacterial cells
hosting random variant enzymes to the extended spectrum
cephalosporins most frequently used in clinical settings [45].
Figure 9. Median-joining network inferred for all CTX-M amino acid sequences studied. Numbers next to the segments connecting nodes
denote the number of amino acid positions inferred to have changed between the two connected alleles, when these are larger than one. The major
groups identified with this analysis correspond to the groups also defined in the phylogenetic tree shown in Figure 1.
doi:10.1371/journal.ppat.1000735.g009
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antibiotic drivers contribute to the increase in frequency of a
wealth of mutational variants, so as to provide the necessary
genetic background for a number of different accessible evolu-
tionary paths. Antimicrobial agents should not be considered only
as selectors for the most efficient resistance mechanisms but, by
selecting at intermediate steps, they also act as diversifying agents
of the evolutionary trajectories, since they contribute to shaping
the adaptive landscape in which evolution has to occur.
Materials and Methods
CTX-M sequence alignments and phylogeny
Thirty-one blaCTX-M-1 group nucleotide sequences available at
the GenBank database (http://www.ncbi.nlm.nih.gov) at the
beginning of this study were analyzed. Sequences (n=42)
belonging to other CTX-M clusters (22 blaCTX-M-9,1 2blaCTX-M-2,
3 blaCTX-M-8 and 4 blaCTX-M-25, and the recombinant form
blaCTX-M-64) along with 12 blaKLU genes from putative Kluyvera
spp. ancestors were included in order to perform a comprehensive
analysis. The corresponding translated amino acid sequences were
aligned using CLUSTALW [46], and gaps were inserted in the
respective coding sequences in order to obtain a codon-based
alignment which was used for the ensuing phylogenetic inference
analyses. The alignment was manually revised and modified where
necessary.
Bayesian and maximum likelihood phylogenetic trees were
obtained using MrBayes 3.1.2 [47] and PHYML [48]. The
Tamura-Nei nucleotide substitution model, selected with the
ModelTest program [49] according to the Akaike information
criterion (AIC), was used as evolutionary model and included a
gamma distribution with six rate categories and a fraction of
invariant sites to account for substitution rate heterogeneity among
sites. The robustness of the maximum-likelihood topology was
evaluated by the approximate likelihood ratio method [50] with
1000 bootstrap pseudorandom replicates. Additionally, a neigh-
bor-joining tree [51] with 1000 bootstrap replicates was con-
structed using MEGA [52]. The topology resulting from likelihood
analyses was used for the ensuing positive selection analyses after
converting branch lengths to substitutions per codon-site.
An alternative method to reconstruct the genealogical relation-
ships among closely related gene variants was also used. A median-
joining network [53] was constructed using Networks version
4.5.1.0 (available at http://www.fluxus-technology.com) with
amino acid sequences corresponding to all blaCTX-M-1 variants
studied.
Reconstruction of the CTX-M-1 cluster
In order to infer the most likely ancestral amino acid sequence
at each internal node of the maximum-likelihood topology
obtained, parsimony analyses of the 22 different positions among
b-lactamases belonging to the CTX-M-1 cluster (12, 19, 23, 27,
35, 38, 67, 77, 89, 106, 114, 119, 140, 158, 167, 238, 240, 263,
271, 278, 279, 288, according to Ambler’s numeration) [54] were
performed using MESQUITE 2.6 [55]. We mapped these
ancestral sequences onto the phylogeny and determined the
extant sequences which retain the same states as the ancestral one.
Models used to determine amino acid positions under
positive selection in CTX-M-1 group enzymes
Amino acid positions in the CTX-M-1 cluster that were
presumably subjected to positive selection were identified by the
application of different selection tests using codon-based substitu-
tion models implemented in the PAML package [56]. According
to these tests, the codon-by-codon ratio (v) of the number of non-
synonymous substitutions per non-synonymous site (dN) to the
number of synonymous substitutions per synonymous site (dS),
(v=dN/dS) was calculated, with values of v.1 indicating positive
selection whilst values of v,1 indicate purifying selection and
values of v=1 represent neutral evolution.
The M7-M8 codon-based maximum-likelihood (ML) substitu-
tion models on an alignment of the CTX-M-3-like sequences were
used in the analyses [57]. In the M7 model, the proportion of sites
with different v in the alignment is fitted by a b distribution with
values between 0 (purifying selection) and 1 (neutral selection).
The M8 model allows sites with v.1, thus adding an extra class of
sites, those evolving under positive selection, to the M7 model. A
likelihood ratio test (LRT) was used in order to detect significantly
better fit of the M8 model with respect to the M7, assuming a chi-
squared null distribution. When the test was significant, Bayesian
probabilities of the different site classes were calculated using a
Bayes empirical Bayes procedure (BEB) [58] and those sites with
an a posteriori probability of having a v.1 higher than 0.95 were
considered to have evolved under positive selection. Additionally,
a branch-site model [59] was used to test whether the evolution of
the CTX-M-1 cluster was accompanied by positive selection
acting on some coding sites while the remaining clusters were
under the constraint of v#1.
Experimental validation of the phylogenetic
reconstruction
According to the predictions endorsed by phylogenetic
inference analyses, the phenotypic consequences of carrying one
or several amino acid changes suspected to be under positive
selection were investigated by site-directed mutagenesis on a
blaCTX-M-3a background. The analysis of each mutation alone or in
combination with others allowed for experimentally testing the
feasibility of the evolutionary trajectories followed to reach the
most evolved variants according to the phylogenetic analysis (see
below, evaluation of mutational trajectories). All predicted
trajectories were explored by sequential site-directed mutagenesis
[27]. A total of 47 variants were constructed in two steps by using
primers A77V-F, N114D-F, A140S-F, P167S-F and D240G-F in
combination with CTX-MPst-Rv, and primers A77V-R, N114D-
R, A140S-R, P167S-R and D240G-R in combination with CTX-
MEco-Fw (step 1), and primers CTX-MEco-Fw and CTX-MPst-
Rv (step 2) to obtain each complete blaCTX-M gene using fragments
from the previous step as DNA template, as previously described
[23]. The D288N change was obtained by conventional PCR,
using CTX-MEco-Fw and D288N-R oligonucleotides. Oligonu-
cleotide sequences used in this study are described in suppl. Table
S2.
The different blaCTX-M genes were cloned in pBGS18 (Kan
R)
plasmid vector [60] and used to transform Escherichia coli strain
MI1443 (DfrdABCD, DampC, recA, Sm
R) [61]. Briefly, amplified
products of complete blaCTX-M genes (step 2) and pBGS18
plasmid were purified (QIAquick purification and QIAprep Spin
Miniprep kits, Qiagen, GmbH, Hilden, Germany), digested with
enzymes EcoRI and PstI, ligated and the recombinant plasmids
transformed into MI1443 cells, using kanamycin (50 mg/ml) and
cefotaxime (1 mg/ml) as selector agents. Plasmid DNA was
extracted from one single clone per selective plate and re-
transformed into MI1443 cells, selecting only with kanamycin
(50 mg/ml), in order to avoid the selection of membrane
permeability mutants. Recombinant plasmids were purified and
the corresponding bla gene was sequenced to confirm the
presence of the desired mutation [23].
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The MIC values for the different E. coli MI1443 strains carrying
recombinant plasmids containing the different blaCTX-M gene
derivatives were determined by the E-test method, following
manufacturer instructions (AB BioMe ´rieux, Solna, Sweden). The
antibiotics tested were: cefotaxime, ceftazidime, cefepime, cepha-
lotin, cefuroxime, cefoxitin and amoxicillin-clavulanic acid
(Sigma-Aldrich Inc., St. Louis, MO, EUA). The MIC of each
transformant obtained and of the control strain MI1443
(pBGS18+blaCTX-M-3) were assayed in triplicate. The significance
of the difference in MIC values between pairs of mutants was
obtained with Mann-Whitney tests, since the number of replicates
for each MIC estimate was too low for parametric testing.
Evolutionary steps identified as significant according to this
analysis are represented in Figures 4, 5 and 7.
Evaluation of mutational trajectories
To compute the probability of each mutational trajectory,
experimentally generated cefotaxime and ceftazidime MIC values
were used as approximations to the fitness of each variant in the
presence of the corresponding antibiotic. A probability propor-
tional to the gain in fitness (increase in MIC value) was assigned to
each step of each trajectory from the initial to the final variant for
cefotaxime and ceftazidime. Under a selective environment,
negative fitness values equaled zero, since selection cannot
contribute to the fixation of a new, less fit variant. Estimates of
the likelihood of each trajectory were obtained assuming the
strong-selection weak-mutation (SSWM) model [62] according to
Weinreich et al. [27]. Trajectories involving one or more steps with
null probability of being favored by natural selection were
considered to have zero chances of occurring under a selective
framework.
GenBank accession numbers
The nucleotide sequences of blaCTX-M genes used for phylogenetic
analysis were as follows: blaCTX-M-1, X92506; blaCTX-M-2, X92507;
blaCTX-M-3, Y10278; blaCTX-M-4, Y14156; blaCTX-M-5, U95364;
blaCTX-M-6, AJ005044; blaCTX-M-7, AJ005045; blaCTX-M-8,
AF189721; blaCTX-M-9, AF174129; blaCTX-M-10, AF255298;
blaCTX-M-11, AY005110; blaCTX-M-12, AF305837; blaCTX-M-13,
AF252623; blaCTX-M-14, AF252622; blaCTX-M-15, AY044436;
blaCTX-M-16, AY029068; blaCTX-M-17, AY033516; blaCTX-M-18,
AF325133; blaCTX-M-19, AF325134; blaCTX-M-20, AJ416344;
blaCTX-M-21, AJ416346; blaCTX-M-22, AY080894; blaCTX-M-23,
AF488377; blaCTX-M-24, AY143430; blaCTX-M-25, AF518567;
blaCTX-M-26, AY157676; blaCTX-M-27, AY156923; blaCTX-M-28,
AJ549244; blaCTX-M-29, AY267213; blaCTX-M-30, AY292654;
blaCTX-M-31, AJ567481; blaCTX-M-32, AJ557142; blaCTX-M-33,
AY238472; blaCTX-M-34, AY515297; blaCTX-M-35, AB176534;
blaCTX-M-36, AB177384; blaCTX-M-37, AY649755; blaCTX-M-38,
AY822595; blaCTX-M-39, AY954516; blaCTX-M-40, AY750914;
blaCTX-M-41, DQ023162; blaCTX-M-42, DQ061159; blaCTX-M-43,
DQ102702; blaCTX-M-44, D37830; blaCTX-M-45, D89862;
blaCTX-M-46, AY847147; blaCTX-M-47, AY847143; blaCTX-M-48,
AY847144; blaCTX-M-49, AY847145; blaCTX-M-50, AY847146;
blaCTX-M-51, DQ211987; blaCTX-M-52, DQ223685; blaCTX-M-53,
DQ268764; blaCTX-M-54, DQ303459; blaCTX-M-55, DQ343292;
blaCTX-M-56, EF374097; blaCTX-M-57, DQ810789; blaCTX-M-58,
EF210159; blaCTX-M-59, DQ408762; blaCTX-M-60, AM411407;
blaCTX-M-61, EF219142; blaCTX-M-62, EF219134; blaCTX-M-63,
AB205197; blaCTX-M-64, AB284167; blaCTX-M-65, EF418608;
blaCTX-M-66, EF576988; blaCTX-M-67, EF581888; blaCTX-M-68,
EU177100; blaCTX-M-69, EU402393; blaCTX-M-79, EF426798;
blaCTX-M-80, EU202673; blaCTX-M-81, EU136031; blaCTX-M-82,
DQ256091; blaKLUC-1, AY026417; blaKLUC-2, EF057432;
blaKLUG-1, AF501233; blaKLUA-1, AJ272538; blaKLUA-2, AJ251722;
blaKLUA-3, AJ427461; blaKLUA-8, AJ427465; blaKLUA-10, AJ427467;
blaKLUA-12, AJ427469; blaKLUY-1, AY623932; blaKLUY-2, AY623935;
blaKLUY-3, AY824948.
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